Lipoxin Receptor Agonist, May Be a Potential Treatment for Hemorrhagic Shock-Induced Acute Lung Injury

Jie Gong,Hong-Bin Li,Si Guo,You Shang,Shang-Long Yao
DOI: https://doi.org/10.1016/j.mehy.2012.04.010
IF: 4.7
2012-01-01
Medical Hypotheses
Abstract:The main pathogenesis of acute lung injury induced by hemorrhagic shock is increasingly recognized as an inflammatory process. BML-111, a lipoxin receptor agonist, has been demonstrated to promote acute inflammatory resolution by reduction of pro-inflammatory cytokines, attenuation of neutrophilic infiltration, and increasing macrophage phagocytosis of apoptotic neutrophils. Meanwhile, lipoxins and lipoxin analogues have been reported to play pro-resolving and anti-inflammatory effects in many disease models including cerebral ischemia, dorsal air pouch, peritonitis, and so on. Therefore, we hypothesize that BML-111 may be implicated in pathogenesis of hemorrhagic shock-induced acute lung injury.
What problem does this paper attempt to address?